Company: IOBT
Filing Date: 2025-07-24
Form Type: S-3
Source: 0001193125-25-164495
Chunk: 12

Company: IO Biotech, Inc.
Filing Date: 2025-07-24
Form: S-3
Chunk 12
---
-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described in the section titled “Risk Factors” and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Some of the key factors that could cause actual results to differ from our expectations include:

| • |     | the timing, progress and the success of our clinical trials of Cylembio®, IO112, IO170 and any other product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which 
 the results of the trials will become available and our research and development programs;                                                                                                                                                                                 |

| • |     | whether the results of our trials will be sufficient to support domestic or foreign regulatory approvals for   
 Cylembio® and potential future clinical trials of IO112, IO170 or any other product candidates we may develop; |

| • |     | regulatory actions with respect to our product candidates or our competitors’ products and product 
 candidates;                                                                                        |

| • |     | our ability to obtain, including on an expedited basis, and maintain regulatory approval of Cylembio®, IO112, IO170 or any other product candidates we may develop; |

| • |     | the outcomes of our preclinical studies; |

| • |     | our ability to enroll patients in our clinical trials at the pace that we project; |

| • |     | our ability to establish and conduct our clinical programs on our expected timelines; |

| • |     | the costs of development of any of our product candidates or clinical development programs; |

| • |     | the timing and success of our remediation of the material weakness in our internal control over financial 
 reporting described in our Annual Report on Form 10-K;                                                    |

| • |     | our expectation about the period of time over which our existing capital resources will be sufficient to fund our 
 operating expenses and capital expenditures;                                                                      |

| • |     | the potential attributes and clinical benefits of the use of C